At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Martin Dreyling (Ludwig-Maximilians University of Munich, Munich, Germany) discusses novel biologic therapies for the management of patients with non-Hodgkin lymphoma, including a phase II/III study of lenalidomide versus investigators choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).